前收市價 | 246.53 |
開市 | 246.73 |
買盤 | 247.71 x 800 |
賣出價 | 247.80 x 900 |
今日波幅 | 245.33 - 248.42 |
52 週波幅 | 229.86 - 287.32 |
成交量 | |
平均成交量 | 1,472,524 |
市值 | 71.489B |
Beta 值 (5 年,每月) | 0.44 |
市盈率 (最近 12 個月) | 56.50 |
每股盈利 (最近 12 個月) | 4.38 |
業績公佈日 | 2024年5月02日 - 2024年5月06日 |
遠期股息及收益率 | 3.80 (1.54%) |
除息日 | 2024年3月07日 |
1 年預測目標價 | 278.54 |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.
Becton Dickinson said on Thursday it has increased production of medical syringes in the United States after the country's drug regulator recommended not using some China-made syringes as part of its ongoing quality probe. The U.S.-based medical equipment maker — one of the world's largest syringe suppliers — said it had increased manufacturing in its Nebraska and Connecticut facilities, since the U.S. Food and Drug Administration first raised concerns about China-made syringes in November. The FDA had said last year it was looking into reports of leaks, breakages and other quality problems with plastic syringes manufactured in China and that it may prevent such syringes from entering the U.S. market, if necessary.